4.7 million deaths associated with AMR in 2021. Standard antibiotics are becoming less predictable. Causes: overuse, self-medication, agricultural practices. Solution: surveillance, responsible prescribing, and new therapies.
Dr Kaneez Fatima
Over the past decade, antimicrobial resistance (AMR) has shifted from being a specialised topic in microbiology to a central concern in global health policy. Clinicians across different regions increasingly report that infections once considered routine are becoming more difficult to treat. In everyday medical practice, this change is not always dramatic, but it is noticeable. Antibiotics that were previously reliable are now less predictable in their effectiveness, and this trend has begun to influence treatment decisions in hospitals and community healthcare settings.
AMR occurs when microorganisms, including bacteria, viruses, fungi and parasites, develop the ability to survive exposure to medicines designed to eliminate them. Although resistance is a natural evolutionary process, several human-related factors have accelerated its spread in recent decades. The World Health Organization (WHO) has repeatedly warned that antimicrobial resistance now ranks among the most serious threats to global health, food security and development.
Recent international estimates highlight the scale of the problem. Global analyses published in recent years indicate that approximately 4.7 million deaths were associated with bacterial antimicrobial resistance in 2021, including more than one million deaths directly caused by drug-resistant infections. Updated surveillance reports released during 2024 and 2025 suggest that resistance levels continue to increase in several key bacterial pathogens monitored worldwide. These findings imply that a growing share of infections may no longer respond to standard first-line therapies, and may require second-line or third-line therapies with longer treatment duration, more expensive and more toxic when compared with the first-line therapies.
Multiple factors contribute to this pattern. In many countries, antibiotics remain accessible without strict regulation, which encourages self-medication and inappropriate use. Patients may stop treatment early once symptoms improve, inadvertently allowing partially resistant bacteria to survive and multiply. In addition, antimicrobial agents are widely used in agriculture and animal production, where they may be administered to prevent disease or promote growth. These practices create conditions that favour the emergence of resistant strains capable of spreading through food systems, water sources and international travel.
The clinical implications are increasingly evident as hospitals are encountering infections that require longer treatment durations or alternative medications that may be more expensive or associated with greater side effects. Furthermore, modern medical procedures, including organ transplantation, chemotherapy and complex surgeries, depend heavily on effective antibiotics to prevent infection. As resistance increases, maintaining the safety of these interventions becomes more challenging.
Researchers have also begun to emphasise the environmental dimension of antimicrobial resistance. Antibiotic residues entering water systems, combined with inadequate waste management and sanitation, that can contribute to the persistence of resistant organisms beyond healthcare environments. For this reason, many experts advocate a broader “One Health” perspective, recognising the interconnected relationship between human health, animal health and ecological systems.
Looking forward, projections remain concerning. Some modelling studies suggest that antimicrobial resistance could contribute to millions of additional deaths between 2025 and 2050 if current trends continue. While estimates vary, there is broad agreement that the burden of resistant infections will increase without coordinated global intervention. Addressing AMR, therefore, requires sustained investment in surveillance, responsible prescribing practices, infection prevention strategies and the development of new antimicrobial therapies.
In this context, antimicrobial resistance can be viewed as a slow-moving but profound transformation in infectious disease dynamics. Unlike sudden outbreaks, it progresses quietly yet steadily with the potential to undermine decades of medical progress if left insufficiently addressed.
dr***********@***il.com